What is HC Wainwright’s Estimate for SNTI FY2030 Earnings?

Senti Biosciences, Inc. (NASDAQ:SNTI) – Research analysts at HC Wainwright issued their FY2030 EPS estimates for shares of Senti Biosciences in a research report issued on Friday, March 27th. HC Wainwright analyst E. Bodnar expects that the company will post earnings per share of ($0.07) for the year. The consensus estimate for Senti Biosciences’ current full-year earnings is ($14.54) per share.

Senti Biosciences (NASDAQ:SNTI) last issued its quarterly earnings data on Friday, March 27th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.10). The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $1.00 million.

Several other brokerages also recently issued reports on SNTI. Weiss Ratings reiterated a “sell (e+)” rating on shares of Senti Biosciences in a report on Thursday, January 22nd. Wall Street Zen upgraded Senti Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday. Finally, Chardan Capital lifted their price objective on shares of Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $9.00.

Senti Biosciences Price Performance

SNTI stock opened at $0.79 on Monday. The firm has a market capitalization of $20.77 million, a PE ratio of -0.25 and a beta of 2.12. Senti Biosciences has a twelve month low of $0.79 and a twelve month high of $5.10. The stock’s 50 day moving average is $0.95 and its 200-day moving average is $1.38.

Hedge Funds Weigh In On Senti Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new position in shares of Senti Biosciences in the fourth quarter valued at approximately $40,000. Virtu Financial LLC bought a new stake in Senti Biosciences during the fourth quarter worth $46,000. Citadel Advisors LLC bought a new stake in Senti Biosciences during the third quarter worth $117,000. Geode Capital Management LLC boosted its position in Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after purchasing an additional 117,588 shares during the last quarter. Finally, Armistice Capital LLC purchased a new position in Senti Biosciences in the second quarter worth $1,883,000. Hedge funds and other institutional investors own 25.70% of the company’s stock.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.